INCYTE CORP (INCY) Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Sector: Services-Commercial Physical & Biological Research
Industry: Biotechnology
Incyte Corporation NASDAQ:INCY Healthcare · Biotechnology
Mkt Cap $24.36B
EV -
SI 6.3%
Net Cash/Sh -
Prev close $120.27 -0.27%Open $119.95 -0.35%Now $119.53 VOL 818K $ Vol $97.77M RVOL 0.48x
Mkt Cap $24.36B
EV -
VOL 818K sh
$ Vol $97.77M
RVOL 0.48×
SI 6.3%
Net Cash/Sh -
Press Release ● Major
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
The European Commission approved Incyte's Povofortay (povorcitinib) 45 mg and 75 mg as the first once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa in the EU. Approval rests on the Phase 3 STOP-HS1 and STOP-HS2 trials, which met the HiSCR50 primary endpoint at Week 12, with durable responses through Week 54 (up to 71.4% HiSCR50, 57% HiSCR75, 29% HiSCR100) and no new safety signals.
• 22h ago AI analysis › Press Release
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Incyte entered a clinical collaboration with Natera for a Phase II study of INCA33890, its investigational bispecific immunotherapy, in stage 2/3 colorectal cancer patients who completed surgery and adjuvant chemotherapy. Patients will undergo longitudinal Signatera MRD testing for up to 12 months, and those who test MRD-positive without radiographic disease may enroll and receive treatment — a treatment-on-MRD (TOMR) design.
• 7d ago AI analysis › Press Release
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute
businesswire.com • 11d ago Press Release
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte will present more than 30 abstracts across its hematology portfolio at the ASH 2026 Annual Meeting, December 12-15 in New Orleans. Highlights include oral presentations of first-line myelofibrosis data for INCA033989, its first-in-class mutant calreticulin-targeted antibody, plus updated second-line MF and essential thrombocythemia results, and long-term Phase 1/2 data for latarcibart (VGA039) in von Willebrand disease. An investor and analyst event will be held Saturday, December 12, 2026, 7:30-9:00 p.m.
• 13d ago AI analysis › Press Release
Incyte to Present at Upcoming Investor Conferences
Incyte announced it will present at three investor conferences in November: the Wolfe Research Healthcare Conference on Nov 10, and both the Jefferies Global Healthcare Conference and UBS Global Biopharma Conference on Nov 17. All presentations will be webcast live on Investor.Incyte.com and available for replay for 30 days.
• 13d ago AI analysis › Press Release ● Major
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Incyte reported Q3 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% year-over-year, driven by growth across its marketed portfolio. Core growth beyond Jakafi was the highlight: Opzelura net sales rose 36% to $255 million and Hematology/Oncology sales rose 38% to $235 million, while flagship Jakafi grew a slower 4% to $827 million. GAAP results swung to a net loss of $3.86 per share due to a one-time $1.23 billion IPR&D charge from the $1.25 billion Vega Therapeutics acquisition; excluding it, operating income grew 18%.
• 19d ago AI analysis › Press Release
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Incyte presented new Phase 1 data at ESMO 2026 for its KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890 across pancreatic and colorectal cancers. INCB161734 plus mFOLFIRINOX in first-line metastatic PDAC showed an 89% ORR and 100% disease control rate with a 90% six-month PFS landmark; the Phase 3 DAWN-303 is ongoing with topline data expected in 2028. In heavily pretreated KRAS G12D-mutated CRC, INCB161734 plus cetuximab achieved a 36% ORR, supporting a planned Phase 3 DAWN-302 initiation in H1 2027. INCA33890 in first-line MSS CRC with FOLFOX and bevacizumab achieved a 71% ORR and 100% DCR, reinforcing the ongoing Phase 3 NEXERA-303 with topline data expected in 2029.
• 22d ago AI analysis › Press Release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study; Incyte will co-fund the trial and supply INCB161734.
• 24d ago AI analysis › Press Release
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to test petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 with standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study, while Incyte co-funds the trial and supplies INCB161734.
• 24d ago AI analysis › Press Release
REG-Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the Phase 1/2 study, while Incyte will co-fund the trial and supply INCB161734, sharing development cost and risk.
• 24d ago AI analysis › Press Release
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Incyte will present four rapid oral presentations of new oncology data at the ESMO Congress 2026 in Madrid, October 23-27. Featured assets include KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890, both in ongoing Phase 3 programs, plus CDK2 inhibitor INCB123667 in ovarian cancer. Incyte will host an investor event and webcast on October 26, 2026, at 2:30 p.m.
• 29d ago AI analysis › Press Release
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community
businesswire.com • 1mo ago Press Release
Incyte to Report Third Quarter Financial Results
Incyte scheduled its Q3 2026 earnings release and conference call for Thursday, October 29, 2026. The press release will hit at 7:00 a.m. ET with the call at 8:00 a.m. ET, plus a live webcast at Investor.Incyte.com with replays available for up to ninety days.
• 1mo ago AI analysis › Press Release
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
Knight Therapeutics received Brazilian ANVISA approval under the rare disease pathway for NIKTIMVO (axatilimab) to treat chronic graft-versus-host disease after at least two prior lines of systemic therapy. NIKTIMVO is an Incyte product; Incyte is responsible for development, manufacture and supply while Knight commercializes it in Latin America under their expanded 2025 agreement, so the approval opens a new ex-US market for Incyte.
• 1mo ago AI analysis › Press Release
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
MiniMed (Nasdaq: MMED) named Sheila Denton as General Counsel & Corporate Secretary, effective immediately. Denton previously served as General Counsel and Corporate Secretary of Incyte (Nasdaq: INCY), with more than 25 years of experience across pharma and biotech including Boehringer Ingelheim. She succeeds Courtney Nelson Wills, who departed MiniMed after a transitional support period.
• 1mo ago AI analysis › Press Release
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
The FDA approved Atebrioz (zilurgisertib), a once-daily oral ALK2 inhibitor, to reduce new heterotopic ossification in patients aged 12 and older with fibrodysplasia ossificans progressiva. Zilurgisertib was developed by Incyte and licensed worldwide to Mirum Pharmaceuticals, which will launch the drug in the U.S. in October through its Mirum Access Plus program. Efficacy was based on the Phase 2 PROGRESS study, where treated patients saw a 3.2 cm3 mean decrease in new HO lesion volume versus a 24.6 cm3 increase on placebo.
• 1mo ago AI analysis › Press Release
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Incyte will present data from across its Inflammation and Autoimmunity portfolio at the European Academy of Dermatology and Venereology (EADV) 2026 congress in Vienna, September 30 - October 3, with one oral presentation in atopic dermatitis and more than a dozen posters. The slate is anchored by ruxolitinib cream (Opzelura) long-term and real-world studies in atopic dermatitis and vitiligo, including 24-week TRuE-AD4 safety and patient-reported outcomes, plus pooled Phase 3 STOP-HS1/STOP-HS2 results for povorcitinib in moderate-to-severe hidradenitis suppurativa.
• 1mo ago AI analysis › Press Release
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Specialised Therapeutics (ST), a Singapore-headquartered specialty pharma company, expanded its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (OPZELURA) in Australia. Under the expanded agreement, Incyte remains responsible for development and manufacturing of ruxolitinib cream, while ST manages regulatory submissions, medical affairs, marketing, and distribution across Australia, with regulatory and reimbursement submissions to Australian authorities planned in due course. OPZELURA is a topical JAK1/JAK2 inhibitor already approved in the U.S.
• 1mo ago AI analysis › Press Release
Incyte to Present at Upcoming Investor Conferences
Incyte announced that it will present at three investor conferences during September 2026. The scheduled presentations include the Wells Fargo Healthcare Conference on Sept 9, the Cantor Global Healthcare Conference on Sept 10, and the Morgan Stanley Global Healthcare Conference on Sept 16.
• 2mo ago AI analysis › Press Release
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
Partner Knight Therapeutics submitted a supplemental application to Brazilian health authority ANVISA seeking a first-line indication for Incyte's MINJUVI (tafasitamab) in combination with lenalidomide and R-CHOP. The submission targets adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) and was selected for review under Project Orbis.
• 2mo ago AI analysis › Press Release
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
businesswire.com • 3mo ago Press Release
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte granted inducement awards to 24 new employees consisting of 21,556 restricted stock unit shares and options to purchase 18,172 shares. The grants were approved by the compensation committee on August 3, 2026, with an option exercise price of $118.43 per share, equal to the closing price on the grant date.
• 3mo ago AI analysis › Press Release
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Specialised Therapeutics, Incyte's partner in Australia, announced that Minjuvi (tafasitamab) has been listed on the Pharmaceutical Benefits Scheme for adults with relapsed or refractory follicular lymphoma. The listing is supported by Phase 3 inMIND data showing a 57% reduction in the risk of disease progression or death, with median progression-free survival of 22.4 months versus 13.9 months for the control arm.
• 3mo ago AI analysis › Press Release
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
businesswire.com • 3mo ago Press Release ● Major
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Incyte reported Q2 2026 total revenue of $1.67 billion, up 38% year-over-year, with total net sales rising 40% to $1.49 billion driven by broad-based product growth. Jakafi sales increased 7% to $817 million, while Opzelura sales jumped 173% to $450 million including a one-time $246 million benefit from a CMS settlement; Hematology and Oncology portfolio sales climbed 69% to $222 million.
• 3mo ago AI analysis › Press Release
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Halozyme Therapeutics entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, a mutant calreticulin-targeted antibody, using Halozyme's ENHANZE technology. The terms include an upfront payment to Halozyme, eligibility for milestone payments, and royalties on future net sales, with Incyte having the option to nominate up to two additional targets. CEO Dr.
• 3mo ago AI analysis › Press Release
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Incyte announced it will present data from six programs at the ESMO Congress 2026 in Madrid, featuring four rapid oral presentations focused on its solid tumor portfolio. Key presentations include Phase 1 data for KRAS G12D inhibitor INCB161734 in colorectal and pancreatic cancers and TGFβR2×PD-1 bispecific INCA33890 in MSS colorectal cancer, both of which are currently being evaluated in ongoing Phase 3 programs.
• 4mo ago AI analysis › Press Release
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte presented Phase 1/2 data for VGA039 (latarcibart) showing an 81% median reduction in annualized bleeding rates across all von Willebrand disease types. The subcutaneous therapy was safe and well tolerated over multiple doses, with patients switching from IV prophylaxis experiencing bleed reductions of 75-100%.
• 4mo ago AI analysis › Press Release
Incyte to Report Second Quarter Financial Results
Incyte announced it will report its second quarter 2026 financial results on July 28, 2026, with a conference call scheduled for 8:00 a.m. ET. The press release containing the results will be issued at 7:00 a.m. ET on the same day.
• 4mo ago AI analysis › Press Release ● Critical
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte completed its acquisition of Vega Therapeutics from Star Therapeutics for $1.25 billion upfront to expand its hematology portfolio. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease which holds FDA Breakthrough Therapy and orphan drug designations.
• 4mo ago AI analysis › Press Release
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Star Therapeutics announced that complete Phase 1/2 data for VGA039 demonstrated safety and clinically meaningful bleed reduction in patients with von Willebrand disease, supporting the asset's profile as Incyte awaits closing of its acquisition of Vega Therapeutics. The data, which will be presented at the ISTH 2026 Congress, supports the ongoing Phase 3 VIVID-6 study of the subcutaneous prophylactic therapy.
• 4mo ago AI analysis › Press Release ● Major
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte announced a positive opinion from the EMA's CHMP for Opzelura cream to treat moderate atopic dermatitis in adults, positioning it as the first steroid-free topical JAK option in the EU for patients who failed standard therapies. The recommendation is supported by Phase 3 TRuE-AD4 data showing 84.3% of patients achieved EASI75 and 70.6% achieved IGA-TS at Week 24, with significant itch relief observed as early as Day 2.
• 4mo ago AI analysis › Press Release ● Major
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval is based on data from the L-MIND Phase II trial, which showed a 58.8% overall response rate, and the J-MIND Phase Ib/II trial in Japan, which showed a 71.4% response rate.
• 4mo ago AI analysis › Press Release ● Critical
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Incyte and Mirum announced positive pivotal Phase 2 results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP), showing an 81% reduction in new heterotopic ossification lesions and a 99.9% reduction in new lesion volume versus placebo. The FDA has accepted the New Drug Application for zilurgisertib under Priority Review, with a PDUFA target action date set for September 26, 2026.
• 5mo ago AI analysis › Press Release ● Major
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte presented positive Phase 1 data for INCA033989, a first-in-class mutCALR-targeted antibody, at the EHA 2026 Congress, showing rapid and durable clinical responses in patients with myelofibrosis and essential thrombocythemia. In essential thrombocythemia, 70% of patients achieved complete hematologic response with a median onset of ~2 weeks, while in myelofibrosis, the drug demonstrated significant spleen volume reductions and anemia improvements alongside consistent molecular activity.
• 5mo ago AI analysis › Press Release ● Major
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Incyte reported positive pivotal Phase 3 frontMIND trial results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP in previously untreated high-risk DLBCL and HGBL. The combination significantly prolonged progression-free survival, reducing the risk of disease progression or death by 25% (HR 0.75, p=0.0194) compared to R-CHOP alone, with benefits observed across key molecular subgroups.
• 5mo ago AI analysis › Press Release ● Critical
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte has entered a definitive agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion in upfront cash. The deal adds VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio. VGA039 is a first-in-class subcutaneous therapy with Breakthrough Therapy designation. Star Therapeutics is eligible for up to $750 million in additional sales milestones, bringing total potential consideration to $2.0 billion.
• 5mo ago AI analysis › Press Release ● Major
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Incyte and Mirum Pharmaceuticals announced that pivotal Phase 2 results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) will be presented at ENDO 2026. The late-breaking presentation covers Cohort 1 of the placebo-controlled PROGRESS study, which formed the basis of the New Drug Application (NDA) submitted to the FDA.
• 5mo ago AI analysis › Press Release ● Critical
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Incyte reported positive results from its pivotal Phase 3 frontMIND trial, showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with previously untreated, high-risk DLBCL. The combination therapy reduced the risk of disease progression or death by 25% compared to R-CHOP alone (HR 0.75, p=0.0194), with a 2-year PFS rate of 71.1% versus 62.9% for the control arm.
• 5mo ago AI analysis › Press Release
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Incyte will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 8:40 a.m. EDT. The presentation will be webcast live via Investor.Incyte.com and available for replay for 30 days.
• 5mo ago AI analysis › Press Release ● Major
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte expanded its strategic AI collaboration with Genesis Molecular AI, committing $120 million in upfront consideration to accelerate drug discovery. The deal includes an $80 million cash payment and a $40 million equity purchase in Genesis, allowing Incyte to use proprietary data to train Genesis’ GEMS AI platform across at least five new targets.
• 5mo ago AI analysis › Press Release
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
businesswire.com • 5mo ago Press Release
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
businesswire.com • 6mo ago Press Release ● Major
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
businesswire.com • 6mo ago Press Release
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte granted equity inducement awards to new CFO Suketu (Suky) Upadhyay, including options for 38,429 shares, RSUs for 26,343 shares, and 13,171 target performance shares. The stock options have an exercise price of $97.14, equal to the closing price on the grant date, and vest over four years with a cliff.
• 6mo ago AI analysis › Press Release
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
prnewswire.com • 6mo ago Press Release ● Major
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte announced FDA approval of Jakafi XR, a once-daily extended-release formulation of ruxolitinib, for myelofibrosis, polycythemia vera, and graft-versus-host disease. The approval is supported by clinical data showing that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to the standard 25 mg twice-daily dosage.
• 6mo ago AI analysis › Press Release
Incyte to Present at Upcoming Investor Conferences
Incyte announced it will present at two upcoming investor conferences in May 2026. The presentations are scheduled for the BofA Securities 2026 Health Care Conference on May 13 and the RBC 2026 Global Healthcare Conference on May 19.
• 6mo ago AI analysis › Press Release ● Critical
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Incyte delivered a strong Q1 with total revenue of $1.27 billion, up 21% year-over-year, driven by 20% growth in net sales to $1.10 billion. The pipeline generated significant catalysts, including positive Phase 3 results for povorcitinib in nonsegmental vitiligo and the initiation of a pivotal Phase 3 study for INCB161734 in pancreatic cancer.
• 6mo ago AI analysis › Press Release
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
Incyte appointed Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer, effective May 4, 2026. Mr. Upadhyay joins from Zimmer Biomet and previously held senior finance roles at Bristol Myers Squibb, Endo International, and Becton Dickinson.
• 6mo ago AI analysis › Press Release
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
prnewswire.com • 6mo ago Press Release ● Major
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Incyte announced that positive Phase 3 results from the frontMIND study of tafasitamab in first-line diffuse large b-cell lymphoma will be presented at the 2026 ASCO Annual Meeting. Management stated the data support global regulatory submissions, with the full results set to be shared during an oral presentation on May 30.
• 6mo ago AI analysis › Press Release ● Major
Incyte to Report First Quarter Financial Results
businesswire.com • 7mo ago Press Release
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
businesswire.com • 7mo ago Press Release
Incyte Announces Executive Leadership Appointments
businesswire.com • 7mo ago Press Release
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
businesswire.com • 7mo ago Press Release
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
businesswire.com • 8mo ago